Cassava Sciences Invited by the NIH to Participate in Sachs 4th Annual Neuroscience Innovation Forum
April 26, 2021 08:30 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, April 26, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that it has been...
Cassava Sciences Reports First Quarter 2021 Financial Results and Announces Guidance on Clinical Data Release
April 21, 2021 08:30 ET
|
Cassava Sciences, Inc.
- 9 Month Interim Analysis of Open-label Study to be Presented at a Major Scientific Conference in July 2021 as an Oral Presentation - - Initiation of Pivotal Phase 3 Program Remains On-track for 2nd...
Cassava Sciences Announces Full-year 2020 Financial Results and Business Highlights
March 23, 2021 08:30 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, March 23, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results for...
Cassava Sciences Announces Pharmaceutical Supply Agreement for Simufilam
March 09, 2021 09:00 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, March 09, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company developing product candidates for Alzheimer’s disease, today announced...
Cassava Sciences to Present at the H.C. Wainwright Global Life Sciences Conference
March 08, 2021 08:30 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, March 08, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company developing product candidates for Alzheimer’s disease, has been...
Cassava Sciences to Present at SVB Leerink Global Healthcare Conference
February 23, 2021 08:30 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company developing product candidates for Alzheimer’s disease, has been invited...
Cassava Sciences Announces Positive End-of-Phase 2 Meeting with FDA and Outlines Pivotal Phase 3 Program for Simufilam in Alzheimer’s Disease
February 22, 2021 08:30 ET
|
Cassava Sciences, Inc.
- Two Upcoming Phase 3 Studies and a Previously Completed Phase 2 Program Support a New Drug Application Filing for Simufilam in Alzheimer’s disease - - Agreement Reached to Use ADAS-Cog as...
Cassava Sciences Announces Closing of $200 Million Registered Direct Offering
February 12, 2021 17:08 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company” or “Cassava Sciences”), a clinical-stage biotechnology company focused on Alzheimer’s disease,...
Cassava Sciences Announces $200 Million Registered Direct Offering of Common Stock
February 10, 2021 06:15 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company” or “Cassava Sciences”), a clinical-stage biotechnology company focused on Alzheimer’s disease,...
Cassava Sciences Announces Significant Program Progress and Expected Key Milestones in 2021 for Its Clinical Program in Alzheimer’s Disease
February 08, 2021 08:30 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company developing product candidates for Alzheimer’s disease, today announced...